[go: up one dir, main page]

DK3121280T3 - Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf - Google Patents

Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf

Info

Publication number
DK3121280T3
DK3121280T3 DK16187284.1T DK16187284T DK3121280T3 DK 3121280 T3 DK3121280 T3 DK 3121280T3 DK 16187284 T DK16187284 T DK 16187284T DK 3121280 T3 DK3121280 T3 DK 3121280T3
Authority
DK
Denmark
Prior art keywords
production
methods
antisense compositions
antisense
compositions
Prior art date
Application number
DK16187284.1T
Other languages
English (en)
Inventor
Sergio Baroni
Salvatore Bellinvia
Francesca Viti
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Application granted granted Critical
Publication of DK3121280T3 publication Critical patent/DK3121280T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
DK16187284.1T 2008-11-13 2009-11-13 Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf DK3121280T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08425727 2008-11-13
US15229709P 2009-02-13 2009-02-13
EP09756431.4A EP2364360B1 (en) 2008-11-13 2009-11-13 Antisense compositions and methods of making and using same

Publications (1)

Publication Number Publication Date
DK3121280T3 true DK3121280T3 (da) 2025-06-30

Family

ID=42101499

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16187284.1T DK3121280T3 (da) 2008-11-13 2009-11-13 Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
DK09756431.4T DK2364360T3 (da) 2008-11-13 2009-11-13 Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09756431.4T DK2364360T3 (da) 2008-11-13 2009-11-13 Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf

Country Status (23)

Country Link
US (7) US8912154B2 (da)
EP (2) EP2364360B1 (da)
JP (7) JP5719776B2 (da)
KR (2) KR101767145B1 (da)
CN (2) CN107007616A (da)
AU (4) AU2009315898B2 (da)
CA (2) CA3085272A1 (da)
CY (1) CY1119140T1 (da)
DK (2) DK3121280T3 (da)
ES (2) ES3034412T3 (da)
FI (1) FI3121280T3 (da)
HR (2) HRP20170926T1 (da)
HU (2) HUE071668T2 (da)
LT (2) LT2364360T (da)
MX (3) MX346335B (da)
NZ (1) NZ592673A (da)
PL (2) PL3121280T3 (da)
PT (2) PT3121280T (da)
RS (2) RS56049B1 (da)
RU (2) RU2739302C2 (da)
SI (2) SI3121280T1 (da)
SM (2) SMT202500239T1 (da)
WO (1) WO2010054826A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RS56049B1 (sr) 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
KR102099990B1 (ko) 2011-09-15 2020-04-13 노그라 파마 리미티드 항-smad7 요법의 반응성을 모니터링하는 방법
ITCO20120008A1 (it) * 2012-03-01 2013-09-02 Nuovo Pignone Srl Metodo e sistema per monitorare la condizione di un gruppo di impianti
RU2667960C2 (ru) * 2012-04-18 2018-09-25 Ногра Фарма Лимитед Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
US20140122184A1 (en) * 2012-10-29 2014-05-01 Elwha Llc Food Supply Chain Automation Grocery Information System And Method
US20150335763A1 (en) * 2013-01-09 2015-11-26 The Feinstein Institute For Medical Research Hmgb1-binding beads and uses thereof
CN105008394B (zh) * 2013-03-15 2021-10-22 诺格尔制药有限公司 治疗结肠直肠癌的方法
US10006029B2 (en) * 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
CN106573065A (zh) * 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
BR112016030690B1 (pt) 2014-06-27 2023-11-14 Nogra Pharma Limited Compostos moduladores do receptor de arila, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
WO2016059243A2 (en) * 2014-10-17 2016-04-21 Nogra Pharma Limmited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
US20170247695A1 (en) * 2014-10-17 2017-08-31 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
JP6583954B2 (ja) * 2015-01-08 2019-10-02 日東電工株式会社 展示装置および映像展示方法
US9688993B2 (en) 2015-02-13 2017-06-27 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
WO2017055611A2 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
MA44309A (fr) 2015-11-25 2018-10-03 Nogra Pharma Ltd Oligonucléotides antisens il-34 et leurs procédés d'utilisation
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
WO2017144725A1 (en) 2016-02-26 2017-08-31 Nogra Pharma Limited Methods of treating lactose intolerance
WO2018111323A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease
WO2018112235A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
US20190328770A1 (en) 2016-12-30 2019-10-31 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
WO2020152350A1 (en) 2019-01-25 2020-07-30 Nogra Pharma Limited Compositions for use in preventing acne
JP2022521502A (ja) 2019-02-26 2022-04-08 ノグラ ファーマ リミテッド 脆弱ｘ精神遅滞タンパク質干渉オリゴヌクレオチドおよびその使用方法
KR20220098231A (ko) 2019-11-15 2022-07-11 노그라 파마 리미티드 Il-34 안티센스 제제 및 이의 사용 방법
CN115552005A (zh) * 2020-04-24 2022-12-30 诺格拉制药有限公司 Smad7反义寡核苷酸(aso)的组合物及其使用方法
CA3177291A1 (en) 2021-05-17 2022-11-17 Nogra Pharma Limited Il-34 antisense agents and methods of using same
WO2022243299A1 (en) 2021-05-17 2022-11-24 Nogra Pharma Limited Il-34 antisense agents and methods of using same
CA3241316A1 (en) 2021-12-03 2023-06-08 Quralis Corporation Gapmer antisense oligonucleotides with modified backbone chemistries
CN120958131A (zh) 2023-03-28 2025-11-14 诺格拉制药有限公司 用于治疗储袋炎的smad7抑制性反义寡核苷酸(aso)及其使用方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
IT1230576B (it) 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
AU7735194A (en) 1993-09-24 1995-04-10 Peptide Technology Limited Treatment or prevention of Crohn's disease and/or ulcerative colitis
WO1997045091A2 (en) 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
CA2286396C (en) 1997-04-30 2010-07-06 Isis Pharmaceuticals Inc. Oligonucleotides for enhanced bioavailability
IE970794A1 (en) * 1997-09-24 2000-08-23 Elan Corp Plc Composition and method for enhancing paracellular transport across cell layers
WO1999016454A1 (en) 1997-09-26 1999-04-08 Medeva Europe Limited Pharmaceutical composition for the treatment of inflammatory bowel disease
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
CA2329130A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
ES2388968T3 (es) 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
CN1713897B (zh) * 2002-10-16 2012-07-04 武田药品工业株式会社 控释制剂
CA2510465A1 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RU2351315C2 (ru) * 2003-07-24 2009-04-10 Смитклайн Бичам Корпорейшн Пленки, растворяющиеся в полости рта
ITRM20030393A1 (it) 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
BRPI0509271A (pt) * 2004-03-26 2007-09-04 Lek Pharmaceuticals formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)
US20070243249A1 (en) 2004-11-26 2007-10-18 Friesen Albert D Novel formulation of pyridoxal-5'-phosphate and method of preparation
CN101151035A (zh) * 2004-12-02 2008-03-26 Isis制药公司 用于治疗炎性肠病的治疗性反义寡核苷酸组合物
US20060258610A1 (en) * 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
EP1909767A2 (en) 2005-07-28 2008-04-16 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
WO2007047553A2 (en) 2005-10-14 2007-04-26 Zweig Jack I Methods and compositions for treatment of prostate intraepithelial neoplasia
CN1850135A (zh) * 2006-03-09 2006-10-25 陈世忠 一种鸦胆子油肠溶软胶囊制剂及其制备方法和其应用
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
EP2380564B1 (en) * 2007-04-04 2014-10-22 Sigmoid Pharma Limited An oral pharmaceutical composition
RS56049B1 (sr) * 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
US9364495B2 (en) * 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
KR102099990B1 (ko) 2011-09-15 2020-04-13 노그라 파마 리미티드 항-smad7 요법의 반응성을 모니터링하는 방법
RU2667960C2 (ru) 2012-04-18 2018-09-25 Ногра Фарма Лимитед Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
CN105008394B (zh) 2013-03-15 2021-10-22 诺格尔制药有限公司 治疗结肠直肠癌的方法
CN106573065A (zh) 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
KR20170031245A (ko) 2014-07-28 2017-03-20 노그라 파마 리미티드 염증성 장 질환을 진단 및 치료하기 위한 방법 및 조성물
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
WO2016059243A2 (en) 2014-10-17 2016-04-21 Nogra Pharma Limmited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
WO2017055611A2 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
CA3014383A1 (en) 2016-02-24 2017-08-31 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
US20190328770A1 (en) 2016-12-30 2019-10-31 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
LT2364360T (lt) 2017-08-10
HUE071668T2 (hu) 2025-09-28
US20210290656A1 (en) 2021-09-23
US8912154B2 (en) 2014-12-16
EP2364360A1 (en) 2011-09-14
SI3121280T1 (sl) 2025-08-29
JP2021138778A (ja) 2021-09-16
KR20170092719A (ko) 2017-08-11
MX2011005042A (es) 2011-08-17
CA3085272A1 (en) 2010-05-20
JP2014196356A (ja) 2014-10-16
ES3034412T3 (en) 2025-08-18
PL3121280T3 (pl) 2025-09-01
RS66973B1 (sr) 2025-07-31
AU2009315898B2 (en) 2015-07-23
EP3121280B1 (en) 2025-04-09
US20150232854A1 (en) 2015-08-20
JP2017075184A (ja) 2017-04-20
PT3121280T (pt) 2025-07-01
WO2010054826A1 (en) 2010-05-20
CA2743329A1 (en) 2010-05-20
JP2015232039A (ja) 2015-12-24
KR101921014B1 (ko) 2018-11-21
AU2015246097B2 (en) 2018-01-18
HRP20250744T1 (hr) 2025-08-15
AU2009315898A1 (en) 2010-05-20
US9314434B2 (en) 2016-04-19
HUE032368T2 (en) 2017-09-28
US10272047B2 (en) 2019-04-30
RU2011123876A (ru) 2012-12-20
JP6530772B2 (ja) 2019-06-12
JP6095744B2 (ja) 2017-03-15
US20150125523A1 (en) 2015-05-07
CN107007616A (zh) 2017-08-04
RU2593939C2 (ru) 2016-08-10
NZ592673A (en) 2013-01-25
JP7377624B2 (ja) 2023-11-10
PL2364360T3 (pl) 2017-09-29
MX346335B (es) 2017-03-14
HRP20170926T1 (hr) 2017-09-22
US9499819B2 (en) 2016-11-22
SMT202500239T1 (it) 2025-09-12
KR101767145B1 (ko) 2017-08-11
SI2364360T1 (sl) 2017-08-31
KR20110086599A (ko) 2011-07-28
CN102216458A (zh) 2011-10-12
AU2020202813A1 (en) 2020-05-21
FI3121280T3 (fi) 2025-07-02
JP5719776B2 (ja) 2015-05-20
AU2017279624A1 (en) 2018-01-18
JP2012508705A (ja) 2012-04-12
CN102216458B (zh) 2017-05-24
RU2016127232A3 (da) 2019-12-18
AU2015246097A1 (en) 2015-11-12
SMT201700346T1 (it) 2017-09-07
EP3121280A1 (en) 2017-01-25
PT2364360T (pt) 2017-06-27
ES2627745T3 (es) 2017-07-31
US20160222383A1 (en) 2016-08-04
US20190374472A1 (en) 2019-12-12
RU2739302C2 (ru) 2020-12-22
CA2743329C (en) 2020-09-01
EP2364360B1 (en) 2017-03-22
US20170107520A1 (en) 2017-04-20
US20120015033A1 (en) 2012-01-19
CY1119140T1 (el) 2018-02-14
RS56049B1 (sr) 2017-09-29
RU2016127232A (ru) 2018-12-06
US9982264B2 (en) 2018-05-29
MX2023008408A (es) 2023-10-19
JP2019151658A (ja) 2019-09-12
JP2023138750A (ja) 2023-10-02
DK2364360T3 (da) 2017-06-19
LT3121280T (lt) 2025-07-25
AU2017279624B2 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
DK3121280T3 (da) Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
BRPI0920284A2 (pt) composição e método
BRPI0919575A2 (pt) método, e, composição
EP2313553A4 (en) Artificial stone
DK2272339T3 (da) Fremgangsmåder og præparater til anvendelse med geldispensere
EP3988147C0 (en) INSERT SET
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
UA18940S (uk) Шоколад
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
BRPI0809573A8 (pt) composição, e, método
BRPI0823277A2 (pt) Composição, e , método
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK2337837T3 (da) Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf
BRPI0917231A2 (pt) composição
IT1392101B1 (it) Composizione comprendente isoflavoni
BRPI0814167A2 (pt) Composição, e, método
BRPI1006996A2 (pt) composição, método e uso
BRPI0823238A2 (pt) Composição, e, método
BRPI0809678A2 (pt) Métodos
DK2334596T3 (da) Ferriphosphatbaseret sammensætning og anvendelse heraf
EP2357204A4 (en) COMPOSITION
FI20075086A0 (fi) Aromikoostumus
DK2262525T3 (da) Apoaequorin-holdige sammensætninger og fremgangsmåder til anvendelse af de samme